FDA OKs premixed CoSeal
This article was originally published in Clinica
The US FDA has given Angiotech Pharmaceuticals clearance to market a new premixed configuration of its synthetic vascular sealant, CoSeal, for sealing tissue surfaces, suture lines and synthetic grafts. The premixed version of CoSeal simplifies the preparation process and extends the lifespan of the product. Additionally, the consistent nature and stability of the new preparation is "an ideal platform" for a next-generation, drug-loaded version of CoSeal, the Vancouver, Canada firm says.